Corsano Health | Top Cardiovascular Solution Company 2023

MedTech Outlook Magazine

Corsano Health
Revolutionizing Continuous Remote Health Monitoring

Drs. Peter C. Stas, CEO, Corsano HealthDrs. Peter C. Stas, CEO
As the benefits of remote patient monitoring (RPM) grow increasingly evident, wearable devices emerge as the revolutionary reformation of health assessment. Particularly when millions of heart attacks are recorded worldwide per year, the ability to continuously track patient data with RPM devices can help physicians predict future cardiac events more accurately and offer timely, preventative therapy or treatment. Centered on this innovation, Corsano Health, a distinguished, wearable medtech company, has developed the CardioWatch 287 medical bracelet, a best-in-class, remote, vital health monitoring device.

“The CardioWatch 287 stands superior among other wearables because of its ability to provide true continuous data, at high resolution and in raw format, if desired,” says Drs. Peter C. Stas, CEO of Corsano Health. Corsano’s innovative bracelet is ergonomically designed and lightweight, forgoing a screen to ensure uninterrupted transmission of data without the wearer having to turn it on. To encourage continuous wear, the CardioWatch 287 has a battery with an extended life of 8 to 15 days.

Corsano’s CE and EU-MDR certified wearable (FDA 510K expected Q4 2022) measures far more vital parameters than any of its competitors, including heart rate, R-R intervals, ECG, SpO2, electrodermal activity, core body temperature, and photoplethysmograph (PPG) signals. Corsano’s bracelet offers continuous data acquisition and strictly complies with GDPR, ensuring high data security. “After acquiring clinically-validated data within GDPR regulations, our CardioWatch 287 transfers that data to Corsano’s certified health cloud or directly to hospital systems and platforms,” says Stas.

The therapeutic advantages of monitoring multiple vital parameters continuously with the CardioWatch 287 are numerous, as physicians are building an enormous dataset to observe pre- and post-procedures.
They can assess a patient’s condition via the Corsano bracelet and promptly address issues, helping them to avoid being among the statistical one-in-four readmitted within 30 days. Researchers and physicians can also download raw data directly from the Corsano bracelet at varying frequencies of 25Hz, 32Hz, and 128Hz to build PPG curves and look for cardiovascular issues, all the while protecting the privacy of their patients.

Corsano Health is a spin-off of a watch company in Switzerland and was incorporated as the market-facing medical company in the Netherlands to enter the medtech market. Corsano works closely with some of the largest academic hospitals in Europe, including the Charité in Berlin, Germany and The Amsterdam Medical Center in The Netherlands, for improved development of its products and technology.

The CardioWatch 287 stands superior among other wearables because it is medically certified and provides true continuous data, at high resolution

Revolutionizing remote patient monitoring, Corsano’s wearable device offers both intramural and extramural RPM, enabling hospitals to continuously monitor a patient, create databases of that patient data, and perform AI analysis on all cardiovascular conditions, as well as oncology-related illnesses. Corsano designed the CardioWatch 287 bracelet with an in-built API that directly pairs with the device and syncs the data with third-party applications or healthcare institutions. Priced at 100 to 250 euros, the device is extremely cost-effective.

The Corsano CardioWatch 287 bracelet proves its indispensability when it comes to the detection of atrial fibrillation (AF). A reimbursed AF Screening and Monitoring Program is running in Germany. Patients wear the Corsano bracelet on a daily basis to determine any recurrences of cardiac events and the frequency of their occurrence.

With the bracelet’s ability to provide raw data and integrated PPG algorithm to reduce false positives, Corsano recently won a bid from the Dutch Heart Foundation to develop a device that detects ‘unwitnessed cardiac arrest’ and alerts a volunteer network of 110,000. The Corsano bracelet perfectly fit the bill; able to send an alert directly to an emergency dispatch center.

It is such innovative approaches that position Corsano to provide the best-in-class remote vital health monitoring wearables.

Top 10 Cardiovascular Solution Companies - 2023

Company
Corsano Health

Management
Drs. Peter C. Stas, CEO

Description
Corsano Health develops, produces and markets medical smart monitoring devices designed to measure vital parameters 24/7 using wireless, non-invasive, and medically certified technology. Its first product, the Corsano CardioWatch is an essential part of a cardiac arrhythmia screening system that can, by providing a simple and effective method for continuous monitoring of the user’s heart rhythm, help identify the risk of a heart attack in an early phase.

Corsano Health News

Corsano Health launches Cuffless Blood Pressure

Corsano Health is launching the company's CardioWatch EU-MDR certified patient monitoring bracelet with Cuffless Non-Invasive Blood Pressure at ESC in Amsterdam.
THE HAGUE, Netherlands - Corsano Health, announces the addition of Cuffless Blood Pressure measurements to its advanced smart bracelet.
The CardioWatch 287-2 holds an EU-MDR certification as a wireless remote monitoring solution designed for continuous acquisition of physiological data within home and healthcare environments. This encompasses a range of metrics, including heart rate, heart rate variability (R-R interval), respiration rate, activity, sleep patterns, ECG readings, SpO2 levels, body temperature, and blood pressure. The collected data is transmitted wirelessly from the device to a server or health cloud via the associated application or gateway. It is then stored and made accessible for subsequent analysis.
The development of the Corsano Cuffless Non-Invasive Blood Pressure algorithm began in 2019, drawing on arterial line and ABPM data collected from over 500 patients. Validation of the Corsano Blood Pressure algorithm followed ISO 81060-2:2019 guidelines and adhered to the joint statement "A Universal Standard for the Validation of Blood Pressure Measuring Devices" released in 2018 by AAMI, ESH, and ISO. Further validations, including assessments related to long-term use, device positioning, re-calibration, exercise impact, and treatment influence, are presently in progress to ensure alignment with all recommendations from ESH (European Society of Hypertension).
The validation of the Corsano Cuffless Non-Invasive Blood Pressure algorithm by the research team at Reinier de Graaf Hospital will be presented during the European Cardiology Congress scheduled for August 28, 2023.
"Corsano Health's CardioWatch 287-2 enables continuous monitoring of vital signs over extended periods, with un-restricted access to raw data for AI and ML development. This approach allows for early detection of any abnormalities, as it captures fluctuations that may go unnoticed with spot measurements. Continuous monitoring proves especially beneficial for managing chronic conditions like heart disease, where automatic continuous monitoring can significantly improve patient outcomes," says Drs. Peter Stas, CEO of Corsano Health.